Literature DB >> 23221554

N-terminal phosphorylation sites of herpes simplex virus 1 ICP0 differentially regulate its activities and enhance viral replication.

Heba H Mostafa1, Thornton W Thompson, David J Davido.   

Abstract

The herpes simplex virus 1 (HSV-1) infected cell protein 0 (ICP0) is an immediate-early phosphoprotein that transactivates viral gene expression. Evidence suggests that phosphorylation regulates the functions of ICP0, and three regions (termed regions I, II, and III) in the protein are known to be phosphorylated. Mutation of the putative phosphorylation sites within region I, termed Phos 1, which lies in the N-terminal portion of ICP0, impairs the E3 ubiquitin (Ub) ligase and ND10-disrupting activities of ICP0 in cell culture and diminishes viral replication. To identify the specific phosphorylation site(s) or residues responsible for the phenotypes observed with Phos 1, individual residues within region I were mutated to alanine (S224A, T226A, T231A, and T232A) and one double mutant S224A/T226A was constructed. Tissue culture studies demonstrated that the S224A, S224A/T226A, T231A, and T232A mutants were unable to dissociate the cellular protein PML from ND10 and that the S224/T226A mutant was defective in its ability to dissociate the cellular protein Sp100 from ND10. Additionally, the transactivation activity of ICP0 was impaired in the S224A and S224A/T226A mutants. The S224A and S224A/T226A mutant forms were more stable than wild-type ICP0, suggesting that their ability to autoubiquitinate was limited. Moreover, one ICP0 ubiquitination target, USP-7, was also more stable after infection with these two mutants. Lastly, the replication of the S224A and S224A/T226A mutant viruses was reduced in cell culture and in vivo. Overall, our data suggest that specific phosphorylation sites within region I differentially regulate the activities of ICP0, which are required for efficient viral replication.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23221554      PMCID: PMC3571471          DOI: 10.1128/JVI.02588-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA.

Authors:  Andrea Rabellino; Brandon Carter; Georgia Konstantinidou; Shwu-Yuan Wu; Alessandro Rimessi; Lauren A Byers; John V Heymach; Luc Girard; Cheng-Ming Chiang; Julie Teruya-Feldstein; Pier Paolo Scaglioni
Journal:  Cancer Res       Date:  2012-03-09       Impact factor: 12.701

2.  Herpes simplex virus type 1 ICP0 phosphorylation mutants impair the E3 ubiquitin ligase activity of ICP0 in a cell type-dependent manner.

Authors:  Chris Boutell; Roger Everett; Joshua Hilliard; Priscilla Schaffer; Anne Orr; David Davido
Journal:  J Virol       Date:  2008-08-20       Impact factor: 5.103

3.  A viral E3 ligase targets RNF8 and RNF168 to control histone ubiquitination and DNA damage responses.

Authors:  Caroline E Lilley; Mira S Chaurushiya; Chris Boutell; Sebastien Landry; Junghae Suh; Stephanie Panier; Roger D Everett; Grant S Stewart; Daniel Durocher; Matthew D Weitzman
Journal:  EMBO J       Date:  2010-01-14       Impact factor: 11.598

4.  The RING finger domain of Varicella-Zoster virus ORF61p has E3 ubiquitin ligase activity that is essential for efficient autoubiquitination and dispersion of Sp100-containing nuclear bodies.

Authors:  Matthew S Walters; Christos A Kyratsous; Saul J Silverstein
Journal:  J Virol       Date:  2010-04-14       Impact factor: 5.103

5.  Reciprocal activities between herpes simplex virus type 1 regulatory protein ICP0, a ubiquitin E3 ligase, and ubiquitin-specific protease USP7.

Authors:  Chris Boutell; Mary Canning; Anne Orr; Roger D Everett
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

6.  Phosphorylation regulates binding of the human papillomavirus type 8 E2 protein to host chromosomes.

Authors:  Vandana Sekhar; Alison A McBride
Journal:  J Virol       Date:  2012-07-11       Impact factor: 5.103

7.  ICP27 phosphorylation site mutants are defective in herpes simplex virus 1 replication and gene expression.

Authors:  Santos Rojas; Kara A Corbin-Lickfett; Laurimar Escudero-Paunetto; Rozanne M Sandri-Goldin
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

8.  Cellular localization of the herpes simplex virus ICP0 protein dictates its ability to block IRF3-mediated innate immune responses.

Authors:  Patrick Paladino; Susan E Collins; Karen L Mossman
Journal:  PLoS One       Date:  2010-04-29       Impact factor: 3.240

9.  Role of nuclear factor Y in stress-induced activation of the herpes simplex virus type 1 ICP0 promoter.

Authors:  Anna S Kushnir; David J Davido; Priscilla A Schaffer
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

10.  PML contributes to a cellular mechanism of repression of herpes simplex virus type 1 infection that is inactivated by ICP0.

Authors:  Roger D Everett; Sabine Rechter; Peer Papior; Nina Tavalai; Thomas Stamminger; Anne Orr
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

View more
  15 in total

1.  Development of a novel cell-based assay to monitor the transactivation activity of the HSV-1 protein ICP0.

Authors:  Angela M Fowler; Heather E Shinogle; David J Davido
Journal:  Antiviral Res       Date:  2015-04-30       Impact factor: 5.970

2.  Herpes Simplex Virus 1 Mutant with Point Mutations in UL39 Is Impaired for Acute Viral Replication in Mice, Establishment of Latency, and Explant-Induced Reactivation.

Authors:  Heba H Mostafa; Thornton W Thompson; Adam J Konen; Steve D Haenchen; Joshua G Hilliard; Stuart J Macdonald; Lynda A Morrison; David J Davido
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

3.  Herpes simplex virus 1 upregulates p35, alters CDK-5 localization, and stimulates CDK-5 kinase activity during acute infection in neurons.

Authors:  Heba H Mostafa; Jessica M van Loben Sels; David J Davido
Journal:  J Virol       Date:  2015-02-18       Impact factor: 5.103

4.  Thyroid hormone-dependent epigenetic suppression of herpes simplex virus-1 gene expression and viral replication in differentiated neuroendocrine cells.

Authors:  Robert W Figliozzi; Feng Chen; Matthew Balish; Amakoe Ajavon; S Victor Hsia
Journal:  J Neurol Sci       Date:  2014-08-20       Impact factor: 3.181

5.  Two overlapping regions within the N-terminal half of the herpes simplex virus 1 E3 ubiquitin ligase ICP0 facilitate the degradation and dissociation of PML and dissociation of Sp100 from ND10.

Authors:  Mirna Perusina Lanfranca; Heba H Mostafa; David J Davido
Journal:  J Virol       Date:  2013-10-02       Impact factor: 5.103

6.  Avibirnavirus VP4 Protein Is a Phosphoprotein and Partially Contributes to the Cleavage of Intermediate Precursor VP4-VP3 Polyprotein.

Authors:  Sanying Wang; Boli Hu; Weiying Si; Lu Jia; Xiaojuan Zheng; Jiyong Zhou
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

7.  HSV-1 ICP0: An E3 Ubiquitin Ligase That Counteracts Host Intrinsic and Innate Immunity.

Authors:  Mirna Perusina Lanfranca; Heba H Mostafa; David J Davido
Journal:  Cells       Date:  2014-05-20       Impact factor: 6.600

8.  A quantitative assay to monitor HSV-1 ICP0 ubiquitin ligase activity in vitro.

Authors:  Chris Boutell; David J Davido
Journal:  Methods       Date:  2015-04-08       Impact factor: 3.608

9.  SUMO Ligase Protein Inhibitor of Activated STAT1 (PIAS1) Is a Constituent Promyelocytic Leukemia Nuclear Body Protein That Contributes to the Intrinsic Antiviral Immune Response to Herpes Simplex Virus 1.

Authors:  James R Brown; Kristen L Conn; Peter Wasson; Matthew Charman; Lily Tong; Kyle Grant; Steven McFarlane; Chris Boutell
Journal:  J Virol       Date:  2016-06-10       Impact factor: 5.103

Review 10.  The HSV-1 ubiquitin ligase ICP0: Modifying the cellular proteome to promote infection.

Authors:  Milagros Collados Rodríguez; Joseph M Dybas; Joseph Hughes; Matthew D Weitzman; Chris Boutell
Journal:  Virus Res       Date:  2020-05-13       Impact factor: 3.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.